Su X. .2022 .Comparative efficacy and safety of oral anticoagulants for venous thromboembolism in patients with different renal functions: A systematic review, pairwise and network meta-analysis. ” BMJ Open, 12(2) : 048619.
Bonde Nissen,A. Nissen .2018 .Use of oral anticoagulation and association to outcomes in atrial fibrillation patients who develop chronic kidney disease. ” European Heart Journal, 1(Suppl) : .
Agnelli G. . .Oral apixaban for the treatment of acute venous thromboembolism. ” New England Journal of Medicine, 369(2013) : 799-808.
Büller H.R. .2013 .Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ” New England Journal of Medicine, 369(15) : 1406-1415.
Elshafei M.N. . .Comparative effectiveness and safety of direct oral anticoagulants in low body weight patients with atrial fibrillation: A systematic review and meta-analysis,” Cardiovascular Drugs and Therapy. , 39(2025) : 643-660.
Tham D. .2024 .Safety and efficacy of direct oral anticoagulants in chronic kidney disease: A meta-analysis. ” Research and Practice in Thrombosis and Haemostasis, 102584(7) : .
Martinez Calderon,E. Calderon . .Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease: A systematic review and meta-analysis. ” Journal of Nephrology, 38(2025) : 111-126.
Grandone E. . .Position paper on the safety and efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. ” Journal of Nephrology, 34(2021) : 31-38.
Hijazi Z. . .Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY trial analysis. ” Circulation, 129(2014) : 961-970.
Montomoli M. .2022 .Oral anticoagulation in patients with chronic kidney disease and non-valvular atrial fibrillation: The FAERC study. ” Healthcare, 2566(12) : .
Lee K.H. . .Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction,” Europace. , 2(2015) : ii69-ii75.
Jun M. . .Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: A multicenter observational study. ” European Heart Journal - Quality of Care and Clinical Outcomes, 9(2023) : 621-631.
Elfar S. .2022 .Direct oral anticoagulants vs. warfarin in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis,” Frontiers in Cardiovascular Medicine. , 847286 : .
Thompson L.E. . .Personalizing direct oral anticoagulant therapy for a diverse population: Role of race, kidney function, drug interactions, and pharmacogenetics. ” Clinical Pharmacology and Therapeutics, 113(2023) : 585-599.
Elenjickal E.J. . .Anticoagulation in patients with chronic kidney disease. American Journal of Nephrology, 55(2024) : 146-164.
Khadzhynov D. . .Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ” Thrombosis and Haemostasis, 109(2013) : 596-605.
De Vriese A.S. .2015 .Dose-finding study of rivaroxaban in hemodialysis patients. American Journal of Kidney Diseases, 01(2015) : 91-98.
Mavrakanas T.A. . .Apixaban pharmacokinetics at steady state in hemodialysis patients. ” Journal of the American Society of Nephrology, 28(2017) : 2241-2248.
Chan K.E. .2015 .Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ” Circulation, 131(11) : 972-979.
Siontis K.C. .2018 .Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. , 138(15) : 1519-1529.
Sarratt S.C.,Nesbit R.,Moye R. . .Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease. ” Annals of Pharmacotherapy, 51(2017) : 445-450.
Stanifer J.W. .2020 .Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. ” Circulation, 141(17) : 1384-1392.
Miao B. . .Rivaroxaban versus apixaban in nonvalvular atrial fibrillation patients with end-stage renal disease. European Journal of Haematology, 104(2020) : 328-335.
Mavrakanas T.A. . .Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation,”. Clinical Journal of the American Society of Nephrology, 15(2020) : 1146-1154.
Yang F. .2017 .Warfarin utilization and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. ” Heart, 103(11) : 818-826.
De Vriese A.S. . .Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: The Valkyrie study. ” Journal of the American Society of Nephrology, 31(2020) : 186-196.
Coleman C.I. . .Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. American Journal of Medicine, 132(2019) : 1078-1083.